iSpecimen Slashes Biospecimen Shipping Times by 85% with Direct Logistics Model

iSpecimen (NASDAQ: ISPC) has announced a significant overhaul of its logistics operations, implementing a direct shipping model for its human biospecimen marketplace. This strategic shift has resulted in a remarkable 85% reduction in shipping times by eliminating the reliance on centralized processing hubs. The new system streamlines both domestic and international logistics by facilitating direct transport from suppliers to customers. By bypassing multi-step routing, the company aims to enhance the integrity of biological samples and improve overall delivery efficiency. This operational improvement is expected to strengthen iSpecimen's market position by providing faster access to critical research materials. Investors view this move as a positive step toward scaling the company's marketplace model and reducing operational overhead.